- Home
- HSIC vs ROIV Comparison
HSIC vs ROIV Comparison
Compare HSIC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSIC | ROIV |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 14.1B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | HSIC | ROIV |
|---|---|---|
| Price | $77.15 | $23.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $76.50 | $21.94 |
| AVG Volume (30 Days) | 1.2M | ★ 6.7M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.70 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $12,938,000,000.00 | $20,329,000.00 |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $3.34 | $376.94 |
| P/E Ratio | $24.16 | ★ N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $60.56 | $8.73 |
| 52 Week High | $82.49 | $22.45 |
Technical Indicators
Market Signals| Indicator | HSIC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 71.09 |
| Support Level | $71.27 | $20.14 |
| Resistance Level | $77.46 | $21.48 |
| Average True Range (ATR) | 1.40 | 0.77 |
| MACD | 0.16 | 0.09 |
| Stochastic Oscillator | 91.65 | 88.97 |
Price Performance
Historical ComparisonAbout HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.